US EditionWegovy-maker Novo Nordisk to cut 9,000 jobs in restructuring
- Novo Nordisk announced on September 10, 2025, a company-wide restructuring to cut 9,000 jobs globally and simplify its organisation.
- The restructuring follows a profit warning, slowing US sales of Wegovy and Ozempic, and rising competition from Eli Lilly in obesity and diabetes markets.
- About 5,000 of the layoffs will occur in Denmark, representing roughly 11.5% of Novo Nordisk’s 78,400-strong workforce, reallocating resources to growth areas.
- The company expects annual savings of approximately 8 billion Danish crowns , with CEO Mike Doustdar stating, “Our company must evolve as well.”
- The overhaul aims to improve decision speed and prioritize investments, reflecting confidence despite lowering operating profit growth to 4-10% this year.
200 Articles
200 Articles
The Danish pharmaceutical giant Novo Nordisk announced on Wednesday that it will eliminate 11% of its workforce, the equivalent of about 9,000 jobs, due to the increasing competition it faces in its treatments against obesity. Globally known for the success of its drugs for diabetes and obesity, the manufacturer of Ozempic and Wegovy said in a statement that the cuts would allow it to save 8 billion kroner ($1.3 billion) by the end of 2026. Over…
Ozempic maker Novo Nordisk to cut 9,000 jobs | Honolulu Star-Advertiser
Novo Nordisk, the Danish drugmaker behind Ozempic and other weight loss and diabetes drugs, announced today that it would cut 11% of its global workforce as it seeks to lower costs and rejuvenate the company’s growth prospects.
Ozempic Creator Novo Nordisk to Slash 9,000 Jobs by End of 2026
Denmark-based Novo Nordisk, the manufacturer of the popular Ozempic diabetes medication, announced on Sept. 10 that it plans to reduce its global workforce by 9,000 employees by the end of 2026 amid intensifying competition in the obesity market, particularly in the United States. In a company statement, Novo Nordisk said the reduction is needed to increase speed and redirect resources to more growth opportunities within the diabetes and obesity…
Coverage Details
Bias Distribution
- 58% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
